USD 462 Billion
Report ID:
SQMIG35H2127 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
62 |
Figures:
75
Global Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 1125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031).
Biologic drugs are complex in nature and are produced through biotechnological processes, often involving recombinant DNA technology. The purpose of the biologics market is to provide innovative and effective therapies for various diseases and medical conditions. Biologics have revolutionized the treatment landscape, offering targeted and personalized approaches for patients. They are widely used in the treatment of chronic diseases like cancer, autoimmune disorders, and infectious diseases. The market aims to develop and deliver biologics that improve patient outcomes and enhance the quality of life. The driving factors behind the growth of the biologics market is the increasing prevalence of chronic diseases worldwide. The rise in diseases such as cancer, diabetes, and rheumatoid arthritis has created a significant demand for biologics. the need for specialized storage and transportation conditions for biologics, as they are sensitive to temperature and environmental conditions. Maintaining the integrity and stability of biologics throughout the supply chain can be complex and costly.
The global biologics market plays a vital role in providing innovative therapies for various diseases. It aims to improve patient outcomes and enhance the quality of life. While there are driving factors such as the increasing prevalence of chronic diseases and advancements in biotechnology, there are also restraining factors like high costs and complex manufacturing processes. Overcoming these challenges and capitalizing on opportunities in personalized medicine and emerging technologies will shape the future of the biologics market.
US Biologics Market is poised to grow at sustainable CAGR for the next forecast year
Global Market Size
USD 462 Billion
Largest Segment
Microbial
Fastest Growth
Microbial
Growth Rate
10.40% CAGR
To get more reports on the above market click here to Buy The Report
The global biologics market is segmented on the basis of source, manufacturing, and region. By source, the market is segmented into microbial, mammalian, and others. By manufacturing, the market is segmented into outsourced, and in-house. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Biologics Market Analysis by Source
In 2022, the microbial segment held the largest market share of 58.23% in the biologics industry. The majority of approved biologics available today are developed and manufactured using microbial expression systems. Key products, including platelet-derived growth factor, recombinant insulin, granulocyte-macrophage colony-stimulating factor, and recombinant interferons, are produced through microbial expression systems.
The mammalian expression systems segment is anticipated to exhibit significant growth during the forecast period. These expression systems are primarily utilized for developing recombinant proteins and viral-vector based vaccines. Among mammalian cell lines, CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) are the most commonly employed. Notable biologic products manufactured using mammalian expression systems include Perjeta (Pertuzumab), Adcetris (Brentuximab-Vedotin), Shingrix (zoster vaccine), Kadycla (Trastuzumab emtansine), and Aimovig (erenumab).
Biologics Market Analysis by Manufacturing
In 2022, the in-house segment dominated the biologics market with a share of 84.87%. Biologic drug manufacturing is more complex compared to small molecules, involving the use of live microorganism cultures and adherence to strict regulatory requirements. In-house manufacturing offers the advantage of direct control, enabling better day-to-day monitoring of biologic drugs.
The outsourcing segment is projected to grow at a compound annual growth rate (CAGR) of 10.7% during the forecast period. Several Contract Development and Manufacturing Organizations (CDMOs) like WuXi Biologics, Lonza, and Samsung Biologics have established state-of-the-art biologic manufacturing facilities. Collaborating with these CDMOs provides companies access to manufacturing experts, ensuring successful downstream process development and the implementation of new technologies. The growth of the market is greatly influenced by the increasing number of CDMOs and their expansion of production capacity. For example, in November 2022, WuXi Biologics inaugurated its integrated biologics center in Shanghai, a vast facility spanning 1.6 million square feet. This center will provide end-to-end biologics development facilities, including product development, quality control, and manufacturing.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America held the largest share of 44.37% in the biologics market. This can be attributed to several factors. Firstly, the region has a high prevalence of chronic diseases, driving the demand for biologic therapies. Additionally, North America is home to numerous leading pharmaceutical companies, contributing to the growth of the market. Favorable reimbursement policies and substantial investments in research and development further support the market's expansion. According to an article published in JAMA Network, biologics accounted for 37% of total drug spending in the United States. The increasing share of biologic prescriptions and investments in targeted drug development are key factors driving market growth. Moreover, the approval of novel biologic drugs such as gene therapy, antisense, and RNAi therapeutics is expected to propel the market even further.
Asia Pacific is projected to grow at a CAGR of 11.0% during the forecast period. The region is experiencing a rising burden of diseases like cancer, diabetes, and cardiovascular diseases, coupled with an increase in the geriatric population. This has led to an increased demand for biologics in the region. Market leaders in the industry are actively focusing on meeting this demand and making significant investments in the development of advanced biologic products. The adoption of biosimilars is also driving market growth in the Asia Pacific region, as they enhance the accessibility and affordability of biologic therapies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Biologics Market Drivers
Increasing Prevalence of Chronic Diseases
Advancements in Biotechnology
Biologics Market Restraints
High Cost of Biologics
Regulatory Challenges
Request Free Customization of this report to help us to meet your business objectives.
The global biologics market is characterized by intense competition among key market players striving to maintain their market position and gain a competitive edge. The market is dominated by major pharmaceutical companies, biotechnology firms, and contract manufacturing organizations (CMOs) that specialize in biologic drug development and manufacturing. Biotechnology firms also play a significant role in the competitive landscape. Companies like Biogen, Genentech, and Gilead Sciences focus on developing cutting-edge biologics and investing in research to advance scientific understanding and therapeutic options. Biogen's multiple sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made substantial contributions to their market presence.
Biologics Market Top Player’s Company Profiles
Biologics Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
Our global biologics market analysis states that this industry is expected to experience significant growth during the forecast period from 2023 to 2030. The market refers to the industry that focuses on the development, manufacturing, and commercialization of biologic drugs. Biologics are medicines derived from living organisms, such as proteins, antibodies, vaccines, and gene therapies. They offer targeted and personalized treatments for various diseases, including cancer, autoimmune disorders, and rare genetic conditions. The market analysis of the biologics industry involves studying various factors that impact its growth and performance. These factors include market size, revenue trends, market share, and competitive landscape. Market analysis also involves assessing the demand and supply dynamics, pricing trends, regulatory environment, and technological advancements in the industry. The biologics market has witnessed significant growth in recent years due to factors such as the increasing prevalence of chronic diseases, advancements in biotechnology, and rising investments in research and development. Factors influencing regional market growth include the presence of the market analysis of the global biologics market involves assessing various factors that contribute to its growth, understanding the competitive landscape, and evaluating regional dynamics. This analysis helps stakeholders in the industry make informed decisions, identify growth opportunities, and develop effective strategies to navigate the evolving market landscape.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 462 Billion |
Market size value in 2031 | USD 1125.55 Billion |
Growth Rate | 10.40% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Biologics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Biologics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Biologics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Biologics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35H2127